An Official Website of the United States Government
Company Information:
Name:
LIPELLA PHARMACEUTICALS, INC.
Address:
5414 GUARINO RD
PITTSBURGH, PA
PITTSBURGH, PA
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Intravesical Liposome Treatment for Interstitial Cystitis
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Jonathan H. Kaufman
Award Amount:
$99,617.00
Abstract:
DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency, and severe suprapubic and/or pelvic pain.… More
Intravesical Liposome Treatment for Interstitial Cystitis
Award Year / Program / Phase:
2008 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Award Amount:
$750,000.00
Abstract:
DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency,
and severe suprapubic and/or pelvic pain.… More
Bladder drug delivery using intravesical liposomes to treat overactive bladder
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Jonathan H. Kaufman
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): Lipella Pharmaceutical Inc has been successful with development of intravesical liposome for painful bladder syndrome/Interstitial cystitis (PBS/IC). Through SBIR funding, Lipella has been successful in establishing
the pre-clinical safety of its primary… More
Developing Intravesical Liposomes for Interstitial Cystitis
Award Year / Program / Phase:
2009 / STTR / Phase I
Agency:
HHS
Research Institution:
WILLIAM BEAUMONT HOSPITAL
Abstract:
DESCRIPTION (provided by applicant): LP08 is a novel intravesical treatment for interstitial cystitis (IC), a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects quality
of life. In IC/PBS, two distinct subtypes… More
Bladder drug delivery using intravesical liposomes to treat overactive bladder
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Jonathan H. Kaufman – 412-901-0315
Award Amount:
$999,282.00
Abstract:
DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposome nanoparticles to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome… More